PLC Systems Inc. (PLCSF.OB) Receives FDA Approval to Conduct and Expand Pivotal Trial
Roughly 7 million patients worldwide receive interventional cardiovascular therapeutic and diagnostic imaging procedures each year. Approximately 15 percent to 20 percent of all patients undergoing such procedures are at risk of developing Contrast-Induced Nephropathy (CIN), the third leading cause of in-hospital acute renal failure. Medical device company PLC Systems Inc. (OTCBB: PLCSF) develops cardiac and vascular technologies primarily in the United States. The company today announced it has received full approval from the U.S. Food and Drug Administration (FDA) regarding the company’s RenalGuard System, which was developed for interventional cardiology and radiology patients to eliminate toxins. The FDA approved the…